J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

The combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) showed a statistically significant and clinically meaningful improvement in overall survival compared to Tagrisso (osimertinib) in patients with EGFR-mutated non-small cell lung cancer (NSCLC)1 6.

At three years, 61% of patients on Rybrevant plus Lazcluze were still alive, compared to 53% on Tagrisso monotherapy1.

The median overall survival improvement is expected to exceed one year, which could be transformative for patients with EGFR-positive lung cancer6 7.

The Rybrevant-Lazcluze combination is the first and only regimen to show a survival benefit over the current standard of care in this patient population6.

The combination therapy also demonstrated improved progression-free survival, with a median of 23.7 months compared to 16.6 months for Tagrisso2.

The safety profile of the Rybrevant-Lazcluze combination remained consistent with previous findings, with a 10% discontinuation rate due to treatment-related adverse events4.

These results come from the Phase III MARIPOSA trial, which enrolled 1,074 patients with previously untreated EGFR-mutated advanced NSCLC6.

The Rybrevant-Lazcluze combination offers a chemotherapy-free treatment option for patients with EGFR-mutated NSCLC7.

The combination has already received approval from the US Food and Drug Administration as a first-line treatment for this specific patient demographic4.

Full results from the MARIPOSA trial are expected to be presented at an upcoming major medical meeting and shared with global health authorities7.